Assessing the Benefit of Trebananib in Advanced Ovarian Cancer

Researchers tested the angiogenesis inhibitor trebananib combined with the standard of care in patients with advanced ovarian cancer.

Source: CancerNetwork - May 16, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news